FUJIFILM Diosynth Biotechnologies invests US$200 million to open new facility to expand cell therapy capabilities in USA.
The facility will support the construction of a 175,000 square feet. This new facility will become a hub for life science enterprises and academic institutions.
This investment will enhance Fujifilm's manufacturing capacity to facilitate iPSC-derived cell therapies, along with supporting Cytotoxic T lymphocyte (CTL), Chimeric Antigen Receptor (CAR), T-cell Receptor (TCR), Natural Killer (NK), and tissue-derived therapies.
Within the new campus, there will be dedicated space for iPSC cGMP manufacturing, featuring three clean room suites, process development laboratories, warehouse facilities, and administrative areas.
The investment will effectively double the current manufacturing capacity, crucial for advancing iPSC-derived cell therapies from development to commercialisation.
Additionally, the new site will encompass iPSC manufacturing tailored for research and development purposes, catering to drug discovery, assessing drug efficacy, and advancing pharmacology studies.
The complete site, encompassing cell therapy manufacturing, is scheduled to commence operations in spring 2026.
Name FUJIFILM Diosynth Biotechnologies
Type New Construction
Budget US$200 million